News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
442,378 Results
Type
Article (36549)
Company Profile (84)
Press Release (405736)
Multimedia
Podcasts (195)
Webinars (24)
Section
Business (118967)
Career Advice (1234)
Deals (19981)
Drug Delivery (117)
Drug Development (53294)
Employer Resources (170)
FDA (13160)
Job Trends (10440)
News (210397)
Policy (21731)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Standard (2)
Academia (2042)
Academic (1)
Accelerated approval (22)
Adcomms (18)
Allergies (123)
Alliances (30518)
ALS (118)
Alzheimer's disease (1209)
Antibody-drug conjugate (ADC) (239)
Approvals (13393)
Artificial intelligence (439)
Autoimmune disease (115)
Automation (16)
Bankruptcy (185)
Best Places to Work (7727)
BIOSECURE Act (13)
Biosimilars (124)
Biotechnology (53)
Bladder cancer (147)
Brain cancer (47)
Breast cancer (462)
Cancer (3552)
Cardiovascular disease (332)
Career advice (1084)
Career pathing (38)
CAR-T (181)
CDC (44)
Celiac Disease (2)
Cell therapy (508)
Cervical cancer (29)
Clinical research (46989)
Collaboration (1137)
Company closure (1)
Compensation (339)
Complete response letters (35)
COVID-19 (1886)
CRISPR (52)
C-suite (644)
Cystic fibrosis (86)
Data (4633)
Decentralized trials (2)
Denatured (74)
Depression (118)
Diabetes (365)
Diagnostics (4219)
Digital health (37)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (170)
Drug pricing (147)
Drug shortages (34)
Duchenne muscular dystrophy (175)
Earnings (42602)
Editorial (58)
Employer branding (23)
Employer resources (144)
Events (60304)
Executive appointments (735)
FDA (15612)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (8)
Frontotemporal dementia (13)
Funding (977)
Gene editing (119)
Generative AI (40)
Gene therapy (436)
GLP-1 (801)
Government (3655)
Grass and pollen (4)
Guidances (257)
Healthcare (13482)
HIV (46)
Huntington's disease (32)
IgA nephropathy (63)
Immunology and inflammation (171)
Immuno-oncology (38)
Indications (82)
Infectious disease (2072)
Inflammatory bowel disease (131)
Inflation Reduction Act (13)
Influenza (64)
Intellectual property (137)
Interviews (179)
IPO (7996)
IRA (41)
Job creations (2882)
Job search strategy (924)
JPM (65)
Kidney cancer (12)
Labor market (92)
Layoffs (405)
Leadership (27)
Legal (4228)
Liver cancer (75)
Longevity (12)
Lung cancer (549)
Lymphoma (274)
Machine learning (30)
Management (47)
Manufacturing (496)
MASH (135)
Medical device (13608)
Medtech (13655)
Mergers & acquisitions (12601)
Metabolic disorders (1038)
Multiple sclerosis (114)
NASH (18)
Neurodegenerative disease (236)
Neuropsychiatric disorders (72)
Neuroscience (2110)
Neurotech (1)
NextGen: Class of 2026 (4776)
Non-profit (3199)
Now hiring (63)
Obesity (503)
Opinion (220)
Ovarian cancer (126)
Pain (159)
Pancreatic cancer (157)
Parkinson's disease (189)
Partnered (31)
Patents (285)
Patient recruitment (382)
Peanut (46)
People (40209)
Pharmaceutical (18)
Pharmacy benefit managers (20)
Phase 1 (13545)
Phase 2 (20317)
Phase 3 (16982)
Pipeline (3623)
Policy (254)
Postmarket research (1772)
Preclinical (4464)
Press Release (40)
Prostate cancer (197)
Psychedelics (48)
Radiopharmaceuticals (211)
Rare diseases (624)
Real estate (4388)
Recruiting (66)
Regulatory (17270)
Reports (59)
Research institute (1890)
Resumes & cover letters (188)
Rett syndrome (19)
RNA editing (12)
RSV (53)
Schizophrenia (130)
Series A (170)
Series B (121)
Service/supplier (5)
Sickle cell disease (61)
Special edition (27)
Spinal muscular atrophy (124)
Sponsored (35)
Startups (2692)
State (1)
Stomach cancer (12)
Supply chain (79)
Tariffs (54)
The Weekly (119)
Vaccines (725)
Venture capital (83)
Weight loss (365)
Women's health (71)
Worklife (20)
Date
Last 7 days (384)
Last 30 days (1337)
Last 365 days (18925)
2026 (2199)
2025 (19253)
2024 (22952)
2023 (25966)
2022 (34780)
2021 (37221)
2020 (35929)
2019 (31921)
2018 (24441)
2017 (21746)
2016 (21035)
2015 (24303)
2014 (18141)
2013 (14440)
2012 (15571)
2011 (16024)
2010 (14270)
Location
Africa (583)
Alabama (35)
Alaska (2)
Arizona (186)
Arkansas (11)
Asia (27806)
Australia (4529)
California (6422)
Canada (2083)
China (899)
Colorado (304)
Connecticut (321)
Delaware (276)
Europe (58946)
Florida (1089)
Georgia (255)
Hawaii (1)
Idaho (41)
Illinois (640)
India (42)
Indiana (420)
Iowa (17)
Japan (352)
Kansas (99)
Kentucky (23)
Louisiana (21)
Maine (29)
Maryland (969)
Massachusetts (4473)
Michigan (213)
Minnesota (474)
Mississippi (5)
Missouri (82)
Montana (25)
Nebraska (23)
Nevada (73)
New Hampshire (78)
New Jersey (2083)
New Mexico (20)
New York (1775)
North Carolina (924)
North Dakota (5)
Northern California (3099)
Ohio (235)
Oklahoma (11)
Oregon (36)
Pennsylvania (1482)
Puerto Rico (12)
Rhode Island (37)
South America (780)
South Carolina (63)
South Dakota (1)
Southern California (2526)
Tennessee (133)
Texas (1127)
United States (24589)
Utah (221)
Virginia (168)
Washington D.C. (56)
Washington State (448)
West Virginia (4)
Wisconsin (79)
Wyoming (1)
442,378 Results for "ngc medical spa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
January 5, 2026
·
4 min read
Press Releases
Nemysis Limited Announces Investment by Kolinpharma Through Its Parent Company IGEA Holding S.p.A.
November 14, 2025
·
2 min read
Drug Development
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
Processa Pharmaceuticals, Inc. announces it plans to expand the development of Next Generation Capecitabine (“NGC-Cap”) into the treatment of advanced or metastatic breast cancer beginning with its next Phase 2 trial.
January 19, 2024
·
5 min read
Drug Development
Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
Processa Pharmaceuticals, Inc. presented two abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2024, including new Phase 1b data on its Next Generation Capecitabine (NGC-Cap) product.
April 11, 2024
·
7 min read
Press Releases
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
August 19, 2024
·
4 min read
Press Releases
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR
August 12, 2025
·
9 min read
Drug Development
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
Processa Pharmaceuticals, Inc. announces the successful completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine (“NGC-Cap”). From the Phase 1b data, two dosage regimens have been selected for the Phase 2 trial.
January 25, 2024
·
8 min read
Drug Development
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
October 2, 2024
·
3 min read
Legal
Lilly’s Fight to Stop Zepbound Knockoffs Leads to Lawsuit Against Indianapolis Spa
Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and repackaging them into separate doses.
April 7, 2025
·
4 min read
·
Annalee Armstrong
Press Releases
Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
July 30, 2024
·
4 min read
1 of 44,238
Next
